Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), University of Rostock, Schillingallee 68, 18057 Rostock, Germany.
Stem Cells Int. 2013;2013:698076. doi: 10.1155/2013/698076. Epub 2013 Sep 30.
Human Mesenchymal Stem Cells (hMSCs) present a promising tool for regenerative medicine. However, ex vivo expansion is necessary to obtain sufficient cells for clinical therapy. Conventional growth media usually contain the critical component fetal bovine serum. For clinical use, chemically defined media will be required. In this study, the capability of two commercial, chemically defined, serum-free hMSC growth media (MSCGM-CD and PowerStem) for hMSC proliferation was examined and compared to serum-containing medium (MSCGM). Immunophenotyping of hMSCs was performed using flow cytometry, and they were tested for their ability to differentiate into a variety of cell types. Although the morphology of hMSCs cultured in the different media differed, immunophenotyping displayed similar marker patterns (high expression of CD29, CD44, CD73, and CD90 cell surface markers and absence of CD45). Interestingly, the expression of CD105 was significantly lower for hMSCs cultured in MSCGM-CD compared to MSCGM. Both groups maintained mesenchymal multilineage differentiation potential. In conclusion, the serum-free growth medium is suitable for hMSC culture and comparable to its serum-containing counterpart. As the expression of CD105 has been shown to positively influence hMSC cardiac regenerative potential, the impact of CD105 expression onto clinical use after expansion in MSCGM-CD will have to be tested.
人骨髓间充质干细胞(hMSCs)为再生医学提供了一种很有前途的工具。然而,为了获得用于临床治疗的足够细胞,需要进行体外扩增。传统的生长培养基通常含有关键成分胎牛血清。对于临床应用,需要使用化学成分确定的培养基。在这项研究中,研究了两种商业的、化学成分确定的、无血清 hMSC 生长培养基(MSCGM-CD 和 PowerStem)对 hMSC 增殖的能力,并将其与含血清的培养基(MSCGM)进行了比较。使用流式细胞术对 hMSCs 进行免疫表型分析,并测试它们分化为多种细胞类型的能力。尽管在不同培养基中培养的 hMSCs 的形态不同,但免疫表型显示出相似的标记模式(高表达 CD29、CD44、CD73 和 CD90 细胞表面标记物,缺乏 CD45)。有趣的是,与 MSCGM 相比,CD105 在 MSCGM-CD 中培养的 hMSCs 中的表达显著降低。两组均保持间充质多能分化潜能。总之,无血清生长培养基适合 hMSC 培养,与含血清的培养基相当。由于 CD105 的表达已被证明对 hMSC 的心脏再生潜能有积极影响,因此必须测试在 MSCGM-CD 中扩增后 CD105 表达对临床应用的影响。